azomycin has been researched along with Acute Myelogenous Leukemia in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hart, CP; Hsu, YC; Johnson, MK; Lal, D; Portwood, S; Vargas, R; Wang, ES; Wetzler, M | 1 |
| Andreeff, M; Benito, J; Borthakur, G; Bueso-Ramos, C; Cortes, J; Coveler, A; Daver, N; Estey, EH; Faderl, S; Feliu, J; Gu, Y; Gutheil, JC; Jabbour, E; Kadia, T; Kantarjian, H; Konoplev, S; Konopleva, M; Kornblau, S; Lu, H; Melink, TJ; Nguyen, HQ; Pemmaraju, N; Ravandi, F; Thall, PF; Thomas, D; Wei, C; Wilson, WR; Yi, CA | 1 |
| Andreeff, M; Badar, T; Benito, JM; Borthakur, G; Cortes, JE; Faderl, S; Handisides, DR; Harutyunyan, K; Jabbour, E; Kantarjian, HM; Konoplev, S; Konopleva, M; Kroll, S; Pearce, T; Richie, MA; Thomas, DA | 1 |
2 trial(s) available for azomycin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Phase I/II study of the hypoxia-activated prodrug PR104 in refractory/relapsed acute myeloid leukemia and acute lymphoblastic leukemia.
Topics: Adult; Aged; Anemia; Antigens, Neoplasm; Antineoplastic Agents, Alkylating; Biomarkers; Bone Marrow; Carbonic Anhydrase IX; Carbonic Anhydrases; Enterocolitis; Female; Gene Expression; Humans; Hypoxia; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Nitrogen Mustard Compounds; Nitroimidazoles; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prodrugs; Recurrence; Remission Induction; Thrombocytopenia | 2015 |
Phase I study of evofosfamide, an investigational hypoxia-activated prodrug, in patients with advanced leukemia.
Topics: Adult; Aged; Bone Marrow; Esophagitis; Female; Humans; Hyperbilirubinemia; Hypoxia; Leukemia; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Middle Aged; Nitroimidazoles; Phosphoramide Mustards; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Prodrugs; Salvage Therapy; Stomatitis; Young Adult | 2016 |
1 other study(ies) available for azomycin and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Activity of the hypoxia-activated prodrug, TH-302, in preclinical human acute myeloid leukemia models.
Topics: Animals; Antineoplastic Agents; Apoptosis; Bone Marrow; Cell Hypoxia; Cell Line, Tumor; Cell Proliferation; DNA Fragmentation; Female; Histones; HL-60 Cells; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Leukemia, Myeloid, Acute; Mice; Mice, SCID; Nitroimidazoles; Phosphoramide Mustards; Phosphorylation; Protein Processing, Post-Translational; Reactive Oxygen Species; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |